Tissue oxygen saturation measurement during arterial desaturation study

ISRCTN ISRCTN30656608
DOI https://doi.org/10.1186/ISRCTN30656608
Secondary identifying numbers MDT19020
Submission date
21/08/2019
Registration date
09/09/2019
Last edited
04/06/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Current plain English summary as of 12/09/2019:
Background and study aims
Chronic changes in arterial oxygen concentration are used as a measure of severity of disease state for a variety of conditions such as sleep apnea, chronic obstructive pulmonary disease, pulmonary arterial hypertension and heart failure. The aim of this study is to get information about how much oxygen can be detected in the tissues of the chest and the fingers of patients with two or more of these conditions. These conditions lower the amount of oxygen in the body. Doctors use measurements of how much oxygen is in the blood to understand how severe someone’s condition is. The more doctors know about changes to a person’s blood oxygen levels, the earlier they can treat the condition and this can help to keep more people out of the hospital.

Who can participate?
Patients over the age of 18 with one or more of the following conditions: sleep apnea, chronic obstructive pulmonary disease, pulmonary arterial hypertension and heart failure.

What does the study involve?
In order to collect the necessary data for this study, tissue oxygen sensors are placed on the patient's chest and depending on the condition they possess, the patient either undergoes a monitored sleep study or a series of 6-minute walk tests. The data collection visit takes place at a hospital and lasts about 9 hours for sleep study patients and about 45 minutes for 6-minute walk test patients.

What are the possible benefits and risks of participating?
In agreeing to be in this study, there will not be any direct medical benefits. The information from this study may benefit other patients who need monitoring devices for conditions like these in the future. All the risks of using the study devices and having the sleep study or doing a 6-minute walk test are the same whether patients are in the study or not. These risks include, but are not limited to: skin irritation or rash from the adhesives used to attach the sensors to the chest, skin irritation or rash from the adhesive or Velcro that may be used to keep the sensor wires in place for participants doing a sleep study, and for participants doing a sleep study, the wires from the monitor could pose a risk for strangulation.

Where is the study run from?
1. University of Minnesota (USA)
2. Minneapolis Heart Institute (USA)

When is the study starting and how long is it expected to run for?
May 2019 to February 2020 (updated 09/03/2020, previously: March 2020)

Who is funding the study?
Medtronic (USA)

Who is the main contact?
1. Troy Penz
troy.d.penz@medtronic.com
2. Joy Aso
joy.a.aso@medtronic.com


Previous plain English summary:
Background and study aims
Chronic changes in arterial oxygen concentration are used as a measure of severity of disease state for a variety of conditions such as sleep apnea, chronic obstructive pulmonary disease, pulmonary arterial hypertension and heart failure. The aim of this study is to get information about how much oxygen can be detected in the tissues of the chest and the fingers of patients with two or more of these conditions. These conditions lower the amount of oxygen in the body. Doctors use measurements of how much oxygen is in the blood to understand how severe someone’s condition is. The more doctors know about changes to a person’s blood oxygen levels, the earlier they can treat the condition and this can help to keep more people out of the hospital.

Who can participate?
Patients over the age of 18 with two or more of the following conditions: sleep apnea, chronic obstructive pulmonary disease, pulmonary arterial hypertension and heart failure.

What does the study involve?
In order to collect the necessary data for this study, tissue oxygen sensors are placed on the patient's chest and depending on the condition they possess, the patient either undergoes a monitored sleep study or a series of 6-minute walk tests. The data collection visit takes place at a hospital and lasts about 9 hours for sleep study patients and about 45 minutes for 6-minute walk test patients.

What are the possible benefits and risks of participating?
In agreeing to be in this study, there will not be any direct medical benefits. The information from this study may benefit other patients who need monitoring devices for conditions like these in the future. All the risks of using the study devices and having the sleep study or doing a 6-minute walk test are the same whether patients are in the study or not. These risks include, but are not limited to: skin irritation or rash from the adhesives used to attach the sensors to the chest, skin irritation or rash from the adhesive or Velcro that may be used to keep the sensor wires in place for participants doing a sleep study, and for participants doing a sleep study, the wires from the monitor could pose a risk for strangulation.

Where is the study run from?
1. University of Minnesota (USA)
2. Minneapolis Heart Institute (USA)

When is the study starting and how long is it expected to run for?
May 2019 to January 2020

Who is funding the study?
Medtronic (USA)

Who is the main contact?
1. Troy Penz
troy.d.penz@medtronic.com
2. Joy Aso
joy.a.aso@medtronic.com

Contact information

Mr Troy Penz
Public

8200 Coral Sea Street NE
Mounds View
55112
United States of America

Phone +1 (0)763 337 2477
Email troy.d.penz@medtronic.com
Miss Joy Aso
Public

8200 Coral Sea Street NE
Mounds View
55112
United States of America

Phone +1 (0)401 545 4454
Email joy.a.aso@medtronic.com

Study information

Study designProspective multi-center non-randomized acute feasibility clinical study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet Not available in web, please use contact details to request a participant information sheet
Scientific titleTissue oxygen saturation measurement during arterial desaturation study
Study acronymTO-SMART
Study objectivesThe purpose of this clinical feasibility, observational study is to collect tissue oxygen saturation (StO2) data in the pectoral region while simultaneously collecting peripheral capillary oxygen saturation (SpO2) data in patients with the following morbidities: Sleep Apnea (SA), Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH) and Heart Failure (HF).
Ethics approval(s)1. Approved 26/11/2019, University of Minnesota Institutional Review Board (McNamara Alumni Center- Suite 350-2, 200 Oak St. SE, Minneapolis, MN 55455, USA)
2. Approved 14/10/2019, Advarra Institutional Review Board (Advarra, 6940 Columbia Gateway Dr Ste 110, Columbia, MD 21046-2788 USA), ref: MOD00520835
Health condition(s) or problem(s) studiedSleep apnea (SA), chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH) and heart failure (HF)
InterventionThe researchers are targeting four patient populations: SA, COPD, PAH and HF. The COPD/PAH/HF cohort will consist of subjects aged ≥ 18 years who are scheduled to undergo a standard of care (SOC) six-minute walk test (6MWT) and are expected to experience a minimum of 5% arterial oxygen desaturation. The Sleep Apnea cohort will consist of subjects aged ≥ 18 years who are scheduled to undergo a SOC sleep study at a sleep lab and are expected to experience a minimum of 5% arterial oxygen desaturation.

At the enrolment and baseline visit, patients sign the informed consent form (ICF) and their physician collects data pertaining to demographic and health history. This will be when the attending physician assesses if the patient is a good fit for the study. During the data collection visit, tissue oxygen saturation (StO2) and peripheral capillary oxygen saturation (SpO2) will be observed and measured in the patients using sensors. Sleep apnea patients will undergo a sleep study as a means for data collection whereas the COPD/PAH/HF will undergo a series of standard of care 6 Minute Walk Tests. The sleep study and necessary data collection will last approximately 9 hours, whereas the 6 Minute Walk Tests with necessary data collection will run for approximately 45 minutes. At the end of the data collection visit, the subject is able to exit the study. No further follow-up will be required.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)
Primary outcome measureTissue oxygen saturation (StO2) in the pectoral region during tissue oxygen desaturation, measured using external StO2 sensors at a single timepoint
Secondary outcome measuresStandard peripheral capillary oxygen saturation (SpO2), measured using an external SpO2 sensor at a single timepoint
Overall study start date01/05/2019
Completion date17/02/2020

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants30
Total final enrolment33
Key inclusion criteria1. Subject must be ≥ 18 years old
2. Subject (or subject’s legally authorized representative) is willing and able to provide written informed consent
3. Sleep Apnea cohort: subjects undergoing a scheduled SOC sleep study who are expected to experience a minimum of 5% arterial oxygen desaturation
4. COPD/PAH/HF cohort: subjects undergoing a scheduled SOC 6MWT who are expected to experience a minimum of 5% arterial oxygen desaturation
Key exclusion criteria1. Subject has other medical conditions that would limit study participation (per physician discretion)
2. Subject has known allergies to medical adhesives and cannot tolerate placement of NoninTM SenSmartTM EQUANOXTM Advance sensor on chest
3. Subject has a disorder causing poor blood circulation to the fingers or a connective tissue disorder that would interfere with an accurate measurement of SpO2 in the fingers (per physician discretion)
4. Subject is unable or unwilling to participate in study procedures
5. Subject is enrolled in a concurrent study that may confound the results of this study. Co-enrollment is any concurrent clinical study (including registries) requires approval of the study manager or designee
6. Subject with exclusion criteria required by local law
Date of first enrolment01/10/2019
Date of final enrolment17/02/2020

Locations

Countries of recruitment

  • United States of America

Study participating centres

University of Minnesota
717 Delaware Street SE
Minneapolis
55414
United States of America
Minneapolis Heart Institute
13205 Isle Drive Suite 100
Baxter
56425
United States of America

Sponsor information

Medtronic Inc
Industry

8200 Coral Sea Street NE
Mounds View
55112
United States of America

Phone +1 (0)763 337 2477
Email troy.d.penz@medtronic.com
ROR logo "ROR" https://ror.org/00grd1h17

Funders

Funder type

Industry

Medtronic
Private sector organisation / For-profit companies (industry)
Alternative name(s)
Medtronic Inc.
Location
United States of America

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planCurrently there are no plans for publication of this study outside of ISRCTN.com. No additional documents for this study will be made available.
IPD sharing planNo patient data will be made openly available. It will be stored entirely in a Medtronic controlled database for internal use.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 03/06/2020 03/06/2020 No No

Additional files

ISRCTN30656608_BasicResults_03Jun20.pdf
Uploaded 03/06/2020

Editorial Notes

04/06/2020: Ethics approval details added.
03/06/2020: The basic results of this trial have been uploaded as an additional file.
09/03/2020: The following changes were made to the trial record:
1. The recruitment end date was changed from 25/02/2020 to 17/02/2020.
2. The overall end date was changed from 15/03/2020 to 17/02/2020.
3. The total final enrolment was added.
4. The plain English summary was updated to reflect these changes.
12/02/2020: The following changes have been made:
1. The recruitment end date has been changed from 15/01/2020 to 25/02/2020.
2. The overall trial end date has been changed from 31/01/2020 to 15/03/2020 and the plain English summary has been updated to reflect this change.
05/12/2019: The following changes have been made:
1. The recruitment end date has been changed from 29/11/2019 to 15/01/2020.
2. The overall trial end date has been changed from 01/01/2020 to 31/01/2020.
12/09/2019: The plain English summary was updated.